2101945-93-9
Chemical Structure
Enpatoran hydrochloride
Synonym(s): M5049 hydrochloride
- CAS No.: 2101945-93-9
- Formula:C16H16ClF3N4
- Molecular Weight:356.77
IUPAC Name: 5-((3R,5S)-3-amino-5-(trifluoromethyl)piperidin-1-yl)quinoline-8-carbonitrile hydrochloride
InChIKey: OHYZGHQWGHDMRP-ZVWHLABXSA-N
SMILES: [H]Cl.N#CC(C=C1)=C(N=CC=C2)C2=C1N3C[C@@H](C(F)(F)F)C[C@@H](N)C3
Biological Activity: Enpatoran hydrochloride (M5049 hydrochloride) is an orally active and selective TLR7/8 antagonist. Enpatoran hydrochloride inhibits the activation of the downstream type I interferon pathway. Enpatoran hydrochloride is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enpatoran hydrochloride | 99.42% | Enpatoran hydrochloride (M5049 hydrochloride) is an orally active and selective TLR7/8 antagonist. Enpatoran hydrochloride inhibits the activation of the downstream type I interferon pathway. Enpatoran hydrochloride is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morand EF, et al. Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet. Rheumatology. 2026 Jul;8(7):e513-e527.
- [2]. Gaudenzi C, et al. Psoriatic microRNAs induce NK cell activation via an innate immune crosstalk abrogated by the Toll-like receptor 7/8 antagonist Enpatoran. Journal of translational medicine. 2026 Mar 02;24(1):478.
- [3]. Vlach J, et al. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity. The Journal of pharmacology and experimental therapeutics. 2021 Mar;376(3):397-409. [Content Brief]
